HCW Biologics Inc. (HCWB) stock
HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.76−0.01 (-1.65%)
Close on Nov 18, 2026Market cap $1.40MP/E –Yield –
HCW Biologics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
HCW Biologics's ebitda for the twelve months ending Jun 30, 2026 was -$7.08M. For fiscal 2025 it was -$12.12M. The highest annual figure on record is -$5.25M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.12M | – |
| FY2024 | Dec 31, 2024 | -$28.27M | – |
| FY2023 | Dec 31, 2023 | -$24.58M | – |
| FY2022 | Dec 31, 2022 | -$14.36M | – |
| FY2021 | Dec 31, 2021 | -$12.82M | – |
| FY2020 | Dec 31, 2020 | -$5.25M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.04M | – |
| Q1 FY2026 | Mar 31, 2026 | $3.38M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.30M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.12M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.55M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.46M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.56M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.01M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.49M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.80M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.23M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.06M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.41M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.86M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.36M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.74M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.01M | -236.5% |
| Q3 FY2021 | Sep 30, 2021 | -$3.97M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.60M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.25M | – |
| Q4 FY2020 | Dec 31, 2020 | $2.20M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.58M | – |
See a number that looks wrong?